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The gene is composed of 4 exons spanning a region of 
9,520 base pairs. 
Transcription 
The mRNA contains 1507 nucleotides. Alternative 
splicing has not been described. In prostate cancer cell 
lines RKIP transcription is repressed by Snail through 
an E-box in its promoter. Promoter methylation does 
not seem to cause loss of RKIP expression. 
Pseudogene 
RKIP has two putative pseudogenes located on 
chromosomes 2 and 14. These are intronless sequences 




Diagram of the RKIP gene. Exons are depicted as filled boxes and untranslated regions are unfilled boxes. Introns are represented as 




Stereo view of the human RKIP structure prepared with Pymol (Delano, 2002). Pocket residues H86 (left), H118 (right), D70 (top) and 
Y120 (bottom) are indicated. 
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Protein 
Note: RKIP belongs to a highly conserved family of 
phospholipid-binding proteins, which have been 
recognized and studied for several years as PEBP. 
These proteins are represented in eukaryotes, bacteria, 
and archae. One of the interesting properties of some 
PEBP family members is that they are cleaved at the N-
terminus to release an undecapeptide which has been
named hippocampal cholinergic neurostimulating 
peptide (HCNP). 
Description 
RKIP is an 187 amino acid protein with a molecular 
mass of 21-23 kDa. The crystal structures of human, 
bovine and plant PEBPs are solved revealing no 
homologies to domains of known functions. The 
structure of RKIP features a b-fold formed by two anti-
parallel b-sheets, a small C-terminal aba element, and a 
cavity at the surface, which could accommodate a smll 
anion such as a phosphoryl group (see diagram above). 
Amino acids forming this cavity are conserved among 
all PEBP family members and constitute the PEB 
motif. 
Expression 
RKIP and its mammalian homologs are widely 
expressed in tissues; it has been detected in lung, 
oviduct and ovary, mammary glands, uterus, prostate 
epithelium, thyroid, mesenteric lymph node, 
megakaryocytes of the heart; spleen, liver, and 
epididymis, testis, spermatids, Leydig cells, 
steroidogenic cells of the adrenal gland zona fasiculata, 
small intestine, plasma cells, and neural cells such as 
brain oliodendricytes, Schwann cells, and Pukinje cells. 
Localisation 
RKIP is localized in the cytoplasm and at the plasm 
membrane. 
Function 
RKIP inhibits the Raf/MEK/ERK cascade. Identified as 
a Raf-1 interacting protein in a yeast two-hybrid screen, 
RKIP was found to inhibit phosphorylation and 
activation of MEK by Raf-1. RKIP inhibits the 
phosphorylation of the N-region of Raf-1 by (21-
activated kinase) Pak and Src family kinases thereby 
inhibiting activation of Raf-1. PKC phosphorylation f 
RKIP following GPCR stimulation causes its release 
from Raf-1. Classical and atypical PKCs can 
phosphorylate RKIP at serine 153 causing dissociatin 
of the Raf-1 kinase domain and RKIP, indicating that 
PKC can mediate ERK activation through RKIP. Once 
free from Raf-1, RKIP was shown to bind GRK-2 and 
block its activity, promoting and enhancing G protein 




RKIP appears to support macrophage differentiation  
via inhibition of the NFKB pathway. RKIP inhibits the  
NF-kappaB pathway through interaction with NIK, 
TAK1, and IKK. RKIP was a novel effector of 
apoptosis signaling; this may occur by modulation of 
the NF-kappaB pathway and/or the regulation of the 
spindle checkpoint via Aurora B kinase and the spindle 
checkpoint by RKIP. RKIP regulation of Aurora kinase 
B and the spindle checkpoint through Raf-1/MEK/ERK 
signaling influences cell cycle fidelity. 
RKIP has serine protease activity. Purified RKIP was 
found to inhibit the serine proteases thrombin, 
chymotrypsin, and neuropsin. 
HCNP, the N-terminal fragment of RKIP, may play a 
role in phospholipid organization of the myelin sheath 
and septal cholinergic development of the 
hippocampus. HCNP can act on frog cardiac 
mechanical performance, exerting a negative 
inotropism. Results of these experiments suggest that 
RKIP/HCNP may be a new endocrine factor that 
regulates cardiac physiology. RKIP downregulation 
may be associated with the congenital heart disease 
manifested in Down syndrome. RKIP downregulation 
was found in the rat right ventricle and in the 
interventricular septum upon cardiac remodeling. 
RKIP has been found in the male reproductive tract 
with implications in the organization of sperm 
membranes during spermiogenesis. It has been 
identified as a decapacitation factor in mouse 
spermatozoa. RKIP and other proteins inhibited 
progesterone-induced acrosome reaction and zona 
pellucida binding of sperm. 
Homology 
No significant sequence homology to other proteins. 
Humans have two known family members, RKIP and 
PEBP4. RKIP has high sequence identity to mouse, rat, 





Immunohistochemical examination of breast cancer 
lymph node metastases showed significant loss of 
RKIP protein expression compared to normal breast 
duct epithelia and primary tumors. There was a weak 
negative correlation between RKIP expression and 
apoptosis in breast tumors that did not have associated 
lymph node metastases. 
Low levels of RKIP may allow cancer cells to evade 
apoptosis. Breast cancer cell lines expressing low levels 
of RKIP undergo apoptosis following ectopic RKIP 
addition or Taxol treatment, which induced RKIP 
expression. 
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Prostate cancer 
Prognosis 
Decreased protein expression of RKIP may be a 
prognostic marker in prostate cancer, with low RKIP 
levels indicating early PSA failure. 
Oncogenesis 
Low levels of RKIP may protect cancer cells against 
apoptosis. Tumorgenic prostate cancer cell lines 
expressing low levels of RKIP increase their RKIP 
expression following treatment with a 
chemotherapeutic drug, sensitizing the cells to 
apoptosis. Cell lines with higher RKIP expression ca  
be made resistant to apoptosis when RKIP is knocked 
down. 
RKIP is downregulated in prostate cancer progression 
and metastasis. Modulation of RKIP expression in 
prostate cancer cell lines changes invasive ability in 
vitro as well as development of metastases in vivo, with 
loss of RKIP corresponding to increased invasiveness 
and metastatic spread. MEK/ERK activation was 
associated with low or decreased RKIP expression in 
vitro, and vice-versa. 
RKIP mRNA can activate interferon-inducible 2’,5’-
oligoadenylate synthetases (OAS), leading to RNase L 
activation. RNase L deficiency in prostate cancer cell
lines (PC3, Du145, LNCap) is associated with 
resistance to apoptosis through OAS activation. 
Melanoma 
Note: RKIP mRNA and protein expression is reduced 
in melanoma cell lines versus normal melanocytes. AP-
1 activation and ERK1/ERK2 phosphorylation 
decreased in Mel Im cells stably transfected with RKIP 
compared to control transfected cells. 
Immunohistochemical analyses showed reduced RKIP 
in primary melanoma versus normal normal skin, and 
further reduction in melanoma metastases. RKIP may 
act by inhibiting B-Raf kinase activity, as demonstrated 
in melanoma cell lines in vitro. 
Hepatocellular carcinoma 
Note: Hepatocellular carcinoma cell lines and HCC 
liver tissue showed decreased RKIP expression as 
compared to primary human hepatocytes or adjacent 
peritumoral tissues. Low RKIP expression was 
correlated with increased ERK activation and 
modulation of RKIP expression antagonized MAPK 
signaling in vitro. 
Colorectal cancer 
Note: Loss of RKIP, as studied in tissue microarrays of 
MMR-proficient and deficient colorectal cancer 
samples, was a marker of tumor progression and 
metastasis. Diminished RKIP expression was 
significantly positively associated with worse survival. 
Insulinoma / Islet neoplasia 
Note: Insulinomas showed decreased or absent RKIP 
expression as compared to normal nearby islets. β-cell 
line HIT-TI5 proliferation, but not apoptotis, was 
inhibited by RKIP. 
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